Advertisement

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) announced positive data from a Phase 2 trial of a second drug candidate, in addition to Kalydeco, aimed at treating cystic fibrosis. The company said it plans to start pivotal, or Phase 3, trials on VX-809 next year.

VX-809 was tested in combination with Kalydeco, or ivacaftor, a drug for which Vertex received approval earlier this year in both the U.S. and in Europe for treatment of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, F508del.

Advertisement
Advertisement